Regarding IL-22 expression in COVID-19 patients, Albayrak et al. have shown that SARS-CoV-2 infection is characterised by an abnormal expression of IL-22R1 in blood myeloid cells and CD4+ T lymphocytes, suggesting that the IL-22R1/IL-22 axis may have a protective role in the early stages of the SARS-CoV-2 infection, but may shift to a harmful response over time.45 This evidence concerns the gene IL22RA1 and COVID-19.